ASK REDCHAT ANYTHING ABOUT ADAGENE INC.
Adagene Inc. (NASDAQ: ADAG)
Listen to this Section
$3.32
-0.2630
(
-7.35% )
10.6K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| ADG126 (CTLA4) + PembrolizumabDetailsCancer, Solid tumor/s, Colorectal cancer |
Phase 1/2 |
| ADG116 (CTLA4)DetailsSolid tumor/s, Cancer |
Phase 1/2 |
| ADG106 (CD137)DetailsSolid tumor/s, Cancer, Non-small cell lung carcinoma, Breast cancer, ER+/HER2- breast cancer |
Failed |
| ADG126 (CTLA4) + PembrolizumabDetailsSolid tumor/s, Cancer, Colorectal cancer |
Phase 1/2 |
Market Data
|
| Open |
$3.32 |
| Previous Close |
$3.58 |
| Volume |
10.6K |
| Market Cap |
$228.61M |
| Day Range |
$3.32 - $3.58 |
| 52 Week Range |
$1.30 - $4.75 |
| Shares Outstanding |
66.07M |
| Change % |
-7.35% |
| Net Change |
▼ -0.2630 |
| Insider Ownership |
N/A |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2021 |
| Country | China |
| Underwriter | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased:
0.00
| Date |
Type |
Amount Purchased |
Purchaser |
| No records found. |
SEC Filings
| Form Type |
Description |
Pages |
Date |
| schedule |
Other |
1 |
Nov 14, 2025 |
| schedule |
Other |
1 |
Nov 14, 2025 |
| 6-k |
Form 6-K |
3 |
Nov 13, 2025 |
| 6-k |
Form 6-K |
81 |
Aug 12, 2025 |
| 6-k |
Form 6-K |
3 |
Jul 15, 2025 |
| schedule |
Other |
2 |
Jul 02, 2025 |
| 6-k |
Form 6-K |
5 |
Jul 01, 2025 |